Monument Therapeutics raises £1.3m for clinical stage brain research

Macclesfield-based Monument Therapeutics has secured an estimated £1.3m to advance its clinical-stage biotechnology research in psychiatry and neurology. The firm focuses on high-unmet-need areas such as neuroinflammation and cognitive impairment associated with schizophrenia.

Incorporated in 2019, the business operates as an independent spin-out from Cambridge Cognition, having launched in that capacity in 2021. The company applies a precision medicine approach to neuroscience drug development, using proprietary digital biomarkers to identify specific patient sub-types with homogenous neurobiology. This methodology aims to match these patients with targeted compounds, mirroring strategies successfully deployed in oncology.

According to its latest accounts for the year ended 30 June 2025, the company employed seven people. LinkedIn data indicates a headcount of five staff members specializing in the field. Total funding recorded for 2025 reached £902.8k, while the total for 2026 currently stands at £1.1m.

The recent funding documentation was filed in June 2026. James Ronald Openshaw joined the board as a director during the same month.